HOPE-07-MIBC: Disitamab Vedotin Plus Immunotherapy vs Chemoimmunotherapy in Resectable HER2-Expressing MIBC
Clinical trial NCT07608224 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07608224
- Sponsor
- West China Hospital
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2, Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2026-06-20
- Primary completion
- 2030-06-30
- Enrollment
- 240
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.